Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
Inventiva (Euronext Paris and Nasdaq: IVA) said it completed its June 2, 2026 EIB warrant restructuring by issuing 15,677,573 new EIB warrants to the European Investment Bank at €0.01 each. The warrants can be exercised for shares at €0.01 and expire Jan. 4, 2036. Remaining legacy EIB warrants were surrendered and canceled.
How this was made
The 30-second read
Why it matters
Completion replaces remaining legacy EIB Tranche B warrants with new EIB warrants that omit specific contractual anti-dilution protection mechanisms and a put option, aiming to reduce future dilution uncertainty.
Market read
This is a capital-structure clean-up that can influence dilution-risk perception and future financing optionality for IVA shareholders.
What to watch
Warrant exercise timing starts August 30, 2026; traders may need to monitor whether EIB or other holders exercise and how that affects future share count and liquidity.
Background
Inventiva previously announced a comprehensive refinancing with the EIB, including repayment of EIB loans and repurchase/cancellation of legacy EIB warrants in tranches.
Ticker impact
Inventiva completed its EIB warrant restructuring, issuing 15.7M new warrants at €0.01 and canceling remaining legacy EIB warrants.
Likely modest positive bias for dilution risk, but near-term impact may be limited since warrants are out-of-the-money at €0.01 exercise.
The article discloses completion of a capital-structure transaction, including warrant counts, pricing, and removal of anti-dilution/put features, which can affect perceived dilution risk.
Market effects
Biopharma financing structures with EIB warrants may be viewed as less dilutive when anti-dilution features are removed.
Limited, primarily relevant to Euronext Paris and Nasdaq-listed Inventiva holders.
Low, as this is a company-specific refinancing/capital-structure adjustment rather than a sector-wide funding shock.
Counterpoint
The exercise price is €0.01 and the warrants are not listed, so the practical dilution overhang may be more about optics than immediate equity risk.
Key entities
- companyInventiva
Clinical-stage biopharmaceutical company developing lanifibranor for MASH; subject of the EIB warrant restructuring announcement.
- counterpartyEuropean Investment Bank (EIB)
Warrant holder/counterparty that receives new warrants and surrenders legacy warrants for cancellation.
